Treatment Comparisons 4 min read Updated 2026-09-12

Botox vs. Dysport vs. Daxxify vs. Xeomin: Chicago Injector Comparison

Botox is no longer the only botulinum toxin on the market. See how Dysport, Daxxify, Xeomin, and Jeuveau differ from Botox Cosmetic in their FDA-approved uses, their units, and the claims made about them.

CR
By the Chicago Med Spa Reviews editors

Key Takeaways for Chicago Patients

  • Units are brand-specific: each of these five FDA labels says its units cannot be compared to or converted into units of other botulinum toxin products, so compare total quotes, not per-unit prices.
  • In SAKURA-2, a Phase 3 trial of Daxxify for frown lines, the median time until lines returned to moderate or severe on both investigator and patient ratings was 167 days, about 24 weeks (ClinicalTrials.gov).
  • If an injector recommends Xeomin because of how it is formulated, for example by saying it lowers the risk of antibody resistance, ask what evidence that recommendation is based on.
  • Jeuveau's FDA label lists one indication, moderate to severe frown (glabellar) lines, and states it is not approved for any other condition.
  • None of the five labels lists jaw slimming, teeth grinding or TMJ, so masseter treatment with any of these brands is off-label: see masseter Botox in Chicago.

Neurotoxin Comparison Table: FDA-Approved Uses

Here is how five FDA-approved botulinum toxin brands compare, based on the indications in each product's current FDA prescribing information on DailyMed. Onset, longevity and price vary by patient, dose and clinic, so ask your injector about those for your own treatment plan.

Licensed prescribers may use these products off-label, but an off-label use should not be advertised as FDA-approved.

Toxin BrandActive IngredientFDA-Approved Cosmetic Use (Label)Other FDA-Approved Uses (Label)
Botox CosmeticOnabotulinumtoxinAModerate to severe glabellar (frown) lines, lateral canthal lines (crow's feet), forehead lines and platysma bandsNone listed on the Botox Cosmetic label
DysportAbobotulinumtoxinAModerate to severe glabellar lines in adults under 65 years of ageCervical dystonia in adults; spasticity in patients 2 years of age and older
DaxxifyDaxibotulinumtoxinA-lanmModerate to severe glabellar lines in adultsCervical dystonia in adults
XeominIncobotulinumtoxinAModerate to severe glabellar lines, horizontal forehead lines and lateral canthal lines in adultsChronic sialorrhea and upper limb spasticity in patients 2 years of age and older; cervical dystonia and blepharospasm in adults
JeuveauPrabotulinumtoxinA-xvfsModerate to severe glabellar lines in adultsNone: the label states it is not approved for any conditions other than glabellar lines

Why Units Do Not Convert Between Brands

Per-unit prices for different brands cannot be compared directly. Each label says so in its own words: Botox Cosmetic units 'cannot be compared to nor converted into' units of other botulinum toxin products, Dysport's potency units 'are not interchangeable with other preparations of botulinum toxin products,' and the Xeomin, Jeuveau and Daxxify labels carry equivalent statements. Ask for the total cost of your treatment plan rather than comparing unit prices.

What changes the total: the brand, the number of units your injector plans for each area, how many areas you treat, who injects, and whether follow-up visits or packages are included. See how much Botox costs in Chicago and what Chicago med spa pricing actually looks like.

Duration, Formulation and Safety Claims, Checked

Ask what any duration claim for Daxxify is based on. In SAKURA-2, a Phase 3 trial sponsored by Revance Therapeutics, the median time until frown lines returned to moderate or severe on both investigator and patient ratings was 167 days, about 24 weeks (ClinicalTrials.gov NCT03014635). A median is the midpoint across trial participants, not a promise for any one patient.

If an injector recommends Xeomin because of how it is formulated, for example by suggesting it reduces the risk of antibody resistance over time, ask what published evidence supports that at cosmetic doses.

If an injector recommends one brand because it spreads more or less, ask what that is based on. All five labels carry a boxed warning that the effects of botulinum toxin products may spread from the area of injection, and that swallowing and breathing difficulties can be life threatening.

None of the five labels lists masseter, jaw slimming, teeth grinding or TMJ use, and none includes the lips, so masseter Botox and a lip flip are off-label with any of these brands.

Frequently Asked Questions

Why is a Dysport unit priced differently from a Botox unit?

Because their units are not the same measure. The Dysport label states its potency units 'are not interchangeable with other preparations of botulinum toxin products,' and the Botox Cosmetic label says its units cannot be compared to or converted into units of any other botulinum toxin product. A per-unit price for one brand therefore cannot be set against another; compare the total quoted cost for the same treatment plan instead.

Can I switch between Botox and Dysport?

Ask your injector whether switching suits you. Because units do not convert between brands, your injector should plan the new brand's dose on its own terms rather than reuse your old unit count.

Is any of these neurotoxins FDA-approved for jaw slimming or a lip flip?

No. None of the FDA labels for Botox Cosmetic, Dysport, Xeomin, Jeuveau or Daxxify lists masseter, teeth grinding or TMJ use, or includes the lips. See masseter Botox in Chicago and lip flip vs lip filler.

Sources

  1. BOTOX Cosmetic (onabotulinumtoxinA) prescribing information, DailyMed, U.S. National Library of Medicine
  2. DYSPORT (abobotulinumtoxinA) prescribing information, DailyMed, U.S. National Library of Medicine
  3. XEOMIN (incobotulinumtoxinA) prescribing information, DailyMed, U.S. National Library of Medicine
  4. JEUVEAU (prabotulinumtoxinA-xvfs) prescribing information, DailyMed, U.S. National Library of Medicine
  5. DAXXIFY (daxibotulinumtoxinA-lanm) prescribing information, DailyMed, U.S. National Library of Medicine
  6. A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2), ClinicalTrials.gov, U.S. National Library of Medicine
Medical Disclaimer: The information provided in this guide is for educational, consumer vetting, and pricing comparison purposes only and does not constitute formal medical advice, clinical diagnosis, or treatment recommendations. Always schedule a direct in-person consultation with an Illinois-licensed medical professional (MD, DO, APRN, PA) to assess your individual anatomical suitability and medical history.

Related Guides & Resources

View All Chicago Guides

Ready to Connect with a Verified Chicago Injector?

Get matched with top-rated medical spas in your Chicago neighborhood or suburb. No obligation, 100% free consultation scheduling.